1178 related articles for article (PubMed ID: 26152583)
1. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
2. Didehydro-Cortistatin A: a new player in HIV-therapy?
Mousseau G; Valente ST
Expert Rev Anti Infect Ther; 2016; 14(2):145-8. PubMed ID: 26581953
[TBL] [Abstract][Full Text] [Related]
3. Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription.
Mousseau G; Aneja R; Clementz MA; Mediouni S; Lima NS; Haregot A; Kessing CF; Jablonski JA; Thenin-Houssier S; Nagarsheth N; Trautmann L; Valente ST
mBio; 2019 Jul; 10(4):. PubMed ID: 31266880
[TBL] [Abstract][Full Text] [Related]
4. Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat.
Mediouni S; Chinthalapudi K; Ekka MK; Usui I; Jablonski JA; Clementz MA; Mousseau G; Nowak J; Macherla VR; Beverage JN; Esquenazi E; Baran P; de Vera IMS; Kojetin D; Loret EP; Nettles K; Maiti S; Izard T; Valente ST
mBio; 2019 Feb; 10(1):. PubMed ID: 30723126
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.
Kessing CF; Nixon CC; Li C; Tsai P; Takata H; Mousseau G; Ho PT; Honeycutt JB; Fallahi M; Trautmann L; Garcia JV; Valente ST
Cell Rep; 2017 Oct; 21(3):600-611. PubMed ID: 29045830
[TBL] [Abstract][Full Text] [Related]
6. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.
Mousseau G; Clementz MA; Bakeman WN; Nagarsheth N; Cameron M; Shi J; Baran P; Fromentin R; Chomont N; Valente ST
Cell Host Microbe; 2012 Jul; 12(1):97-108. PubMed ID: 22817991
[TBL] [Abstract][Full Text] [Related]
7. The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation.
Mediouni S; Kessing CF; Jablonski JA; Thenin-Houssier S; Clementz M; Kovach MD; Mousseau G; de Vera IMS; Li C; Kojetin DJ; Evans DT; Valente ST
FASEB J; 2019 Jul; 33(7):8280-8293. PubMed ID: 31021670
[TBL] [Abstract][Full Text] [Related]
8. The Block-and-Lock Strategy for Human Immunodeficiency Virus Cure: Lessons Learned from Didehydro-Cortistatin A.
Li C; Mori L; Valente ST
J Infect Dis; 2021 Feb; 223(12 Suppl 2):46-53. PubMed ID: 33586776
[TBL] [Abstract][Full Text] [Related]
9. Unexpected Mutations in HIV-1 That Confer Resistance to the Tat Inhibitor Didehydro-Cortistatin A.
Rice AP
mBio; 2019 Jul; 10(4):. PubMed ID: 31289189
[TBL] [Abstract][Full Text] [Related]
10. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
11. Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat.
Li C; Mousseau G; Valente ST
Epigenetics Chromatin; 2019 Apr; 12(1):23. PubMed ID: 30992052
[TBL] [Abstract][Full Text] [Related]
12. Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
Jin H; Li D; Lin MH; Li L; Harrich D
Viruses; 2020 Apr; 12(4):. PubMed ID: 32276443
[TBL] [Abstract][Full Text] [Related]
13. PIWIL4 Maintains HIV-1 Latency by Enforcing Epigenetically Suppressive Modifications on the 5' Long Terminal Repeat.
He Z; Jing S; Yang T; Chen J; Huang F; Zhang W; Peng Z; Liu B; Ma X; Wu L; Pan T; Zhang X; Li L; Cai W; Tang X; Zhang J; Zhang H
J Virol; 2020 May; 94(10):. PubMed ID: 32161174
[TBL] [Abstract][Full Text] [Related]
14. Selective cell death of latently HIV-infected CD4
Zhang G; Luk BT; Wei X; Campbell GR; Fang RH; Zhang L; Spector SA
Cell Death Dis; 2019 May; 10(6):419. PubMed ID: 31142734
[TBL] [Abstract][Full Text] [Related]
15. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
16. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
17. SAMHD1 Impairs HIV-1 Gene Expression and Negatively Modulates Reactivation of Viral Latency in CD4
Antonucci JM; Kim SH; St Gelais C; Bonifati S; Li TW; Buzovetsky O; Knecht KM; Duchon AA; Xiong Y; Musier-Forsyth K; Wu L
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793958
[TBL] [Abstract][Full Text] [Related]
18. LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds.
Jung U; Takahashi M; Rossi JJ; Burnett JC
Methods Mol Biol; 2016; 1354():255-64. PubMed ID: 26714717
[TBL] [Abstract][Full Text] [Related]
19. Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.
Kyei GB; Meng S; Ramani R; Niu A; Lagisetti C; Webb TR; Ratner L
mBio; 2018 Nov; 9(6):. PubMed ID: 30401776
[TBL] [Abstract][Full Text] [Related]
20. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Painter MM; Zaikos TD; Collins KL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
